These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8807725)

  • 1. Pathophysiology of thromboembolism and its modulation by low-molecular-weight heparins.
    Breddin HK
    Semin Thromb Hemost; 1996; 22 Suppl 1():25-7. PubMed ID: 8807725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of thromboembolism and its modulation by low molecular weight heparins.
    Breddin HK
    Semin Thromb Hemost; 1993; 19 Suppl 1():227-8. PubMed ID: 8395726
    [No Abstract]   [Full Text] [Related]  

  • 3. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular-weight heparins and angiogenesis.
    Norrby K
    APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.
    Vignoli A; Marchetti M; Balducci D; Barbui T; Falanga A
    Haematologica; 2006 Feb; 91(2):207-14. PubMed ID: 16461305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Low molecular weight heparin--1998 status].
    Marbet GA
    Praxis (Bern 1994); 1999 Apr; 88(18):802-7. PubMed ID: 10409877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-anticoagulant effects of unfractionated and low-molecular weight heparins.
    Walenga JM
    Clin Adv Hematol Oncol; 2007 Oct; 5(10):759-60. PubMed ID: 17998892
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke.
    Padma V; Fisher M; Moonis M
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):405-15. PubMed ID: 16716101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Low-molecular-weight heparins].
    Rocha E; Páramo JA; Sarrá J
    Med Clin (Barc); 1993 Apr; 100(16):620-7. PubMed ID: 8388527
    [No Abstract]   [Full Text] [Related]  

  • 11. [Low molecular weight heparins].
    Taurand S
    Soins; 1990 Dec; (543):I-II. PubMed ID: 1965350
    [No Abstract]   [Full Text] [Related]  

  • 12. Low molecular weight heparins: the future of thromboembolic therapy.
    Dobbin KR
    Nurse Pract; 1998 Mar; 23(3):98,101-4,106-7. PubMed ID: 9560832
    [No Abstract]   [Full Text] [Related]  

  • 13. [New medical anticoagulants].
    Choussat R; Montalescot G
    Rev Mal Respir; 1999 Nov; 16(5 Pt 2):985-95. PubMed ID: 10907447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
    Buchanan MR; Brister SJ
    Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparins: do we have the GUSTO to identify differences between alternative formulations?
    Zakarija A; Bennett CL
    Arch Intern Med; 2005 Apr; 165(7):722-3. PubMed ID: 15824289
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of taurolidine on experimental thrombus formation.
    Kaptanoglu L; Kucuk HF; Colak E; Kurt N; Bingul SM; Akyol H; Torlak OA; Yazici F
    Eur J Pharmacol; 2008 Jan; 578(2-3):238-41. PubMed ID: 17961549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heparin therapy: 1998 (current use of the 80-year-old heparin)].
    Rák K
    Orv Hetil; 1999 Jan; 140(2):59-66. PubMed ID: 9949661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of microvascular thromboembolism in vivo.
    Egbrink MG; Van Gestel MA; Broeders MA; Tangelder GJ; Heemskerk JM; Reneman RS; Slaaf DW
    Microcirculation; 2005; 12(3):287-300. PubMed ID: 15814437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.